Intensic 100mg Injection contains Irinotecan 20mg/ml, a chemotherapeutic agent classified as a topoisomerase I inhibitor, indicated for the treatment of metastatic colorectal cancer and other solid tumors. Irinotecan exerts its antineoplastic effect by inhibiting the enzyme topoisomerase I, which is essential for DNA replication and transcription, leading to DNA damage and apoptosis in rapidly dividing cancer cells. Intensic 100mg Injection is administered intravenously, typically as part of combination chemotherapy regimens, including FOLFIRI (folinic acid, fluorouracil, and irinotecan). Dosage and administration should be individualized based on patient tolerance, hepatic function, and prior treatment history. Common adverse reactions include neutropenia, diarrhea (which may be early-onset cholinergic or late-onset secretory), nausea, vomiting, and fatigue. Close monitoring of blood counts and supportive care measures are essential to manage toxicity. Dose adjustments may be required in patients with hepatic impairment or severe myelosuppression. Intensic 100mg Injection is contraindicated in patients with known hypersensitivity to irinotecan or its components. Caution is advised in patients with pre-existing gastrointestinal disorders or compromised bone marrow function. This medication should be administered under the supervision of an experienced oncologist in a healthcare setting equipped to manage chemotherapy-related complications.